TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35752023

Group type: EXPERIMENTAL
Intervention: Early parent sips, late peer/parent whole drinks
Number of subjects: 1813

Group type: EXPERIMENTAL
Intervention: Late peer/parent whole drinks
Number of subjects: 1813

Group type: EXPERIMENTAL
Intervention: Early parent sips, mid peer/parent whole drinks
Number of subjects: 1813

Group type: EXPERIMENTAL
Intervention: Early peer/parent whole drinks
Number of subjects: 1813
Study: 35752194

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2-positive children (cases)
Number of subjects: 10997
Study: 35752220

Group type: EXPERIMENTAL
Intervention: Cumulative ACE scores
Number of subjects: 798

Group type: EXPERIMENTAL
Intervention: Reports of sexual abuse
Number of subjects: 798

Group type: EXPERIMENTAL
Intervention: Anxiety and depressive thoughts
Number of subjects: 798
Study: 35752286

Group type: EXPERIMENTAL
Intervention: rs9914222 variant (associated with plasma FGF21 levels)
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Knockdown of SNHG16 in HepG2 cells
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Ethanol exposure in iPSC-derived brain organoids
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Plasma FGF21 levels
Number of subjects: 442
Study: 35752539

Group type: EXPERIMENTAL
Intervention: DASH-aligned congregate meals and SMBP monitoring
Number of subjects: 94
Study: 35752730

Group type: EXPERIMENTAL
Intervention: Insulin degludec/insulin aspart (IDegAsp)
Number of subjects: 1102
Study: 35752812

Group type: EXPERIMENTAL
Intervention: Culturally sensitive, narrative decision aid video
Number of subjects: 30
Study: 35753092

Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy and statins adherence
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: First year follow-up
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Plaque progression
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Mortality during follow-up
Number of subjects: 307
Study: 35753512

Group type: EXPERIMENTAL
Intervention: Exome sequencing, chromosomal microarray, phenotyping, results return with genetic counseling, and reanalysis
Number of subjects: 1505
Study: 35754975

Group type: EXPERIMENTAL
Intervention: BCI EEG-based neurofeedback intervention over six weeks
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: BCI EEG-based neurofeedback intervention
Number of subjects: 5
Study: 35755024

Group type: EXPERIMENTAL
Intervention: AIDA International Registry for USAIDs patients
Number of subjects: 290
Study: 35756655

Group type: EXPERIMENTAL
Intervention: Sintilimab combined with pemetrexed and platinum
Number of subjects: 0
Study: 35756842

Group type: EXPERIMENTAL
Intervention: Ezabenlimab (anti-PD-1 antibody)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BI 754111 (anti-LAG-3 antibody)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of ezabenlimab and BI 754111
Number of subjects: 0
Study: 35756843

Group type: EXPERIMENTAL
Intervention: Olaparib + Immune Checkpoint Blockade (ICB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Olaparib
Number of subjects: 0
Study: 35756891

Group type: EXPERIMENTAL
Intervention: Mobile application for clinical monitoring of patients prescribed home oxygen therapy
Number of subjects: 0
Study: 35757113

Group type: EXPERIMENTAL
Intervention: Competency-based tracheostomy education course
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 44
Study: 35757239

Group type: EXPERIMENTAL
Intervention: Isokinetic strength training
Number of subjects: 37

Group type: COMPARATOR
Intervention: Isotonic strength training
Number of subjects: 37
Study: 35757242

Group type: EXPERIMENTAL
Intervention: Urinary metabolites, particularly polyphenol microbial metabolites
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Various metabolites related to the intake of coffee, red meat, and fish
Number of subjects: 160
Study: 35757406

Group type: EXPERIMENTAL
Intervention: Participants with morbid obesity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 0
Study: 35758151

Group type: EXPERIMENTAL
Intervention: Örebro Musculoskeletal Screening Questionnaire (ÖMSQ-12-TR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tampa Scale for Kinesiophobia (TSK)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SF-12
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pain Numerical Rating Scale (P-NRS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Internal consistency (Cronbach's alpha)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reliability (ICC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reproducibility
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Known-group validity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cut-off value
Number of subjects: 0
Study: 35758267

Group type: EXPERIMENTAL
Intervention: CT scan before adherence evaluation
Number of subjects: 319
Study: 35758418

Group type: EXPERIMENTAL
Intervention: Pre-exposure prophylaxis (PrEP)
Number of subjects: 1043

Group type: COMPARATOR
Intervention: Control group (daily PrEP users)
Number of subjects: 1043
Study: 35758424

Group type: EXPERIMENTAL
Intervention: Indirect costs associated with pediatric IBD
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Out-of-pocket (OOP) costs associated with pediatric IBD
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Travel distance to clinic
Number of subjects: 243
Study: 35759124

Group type: EXPERIMENTAL
Intervention: PDS 10 mg/ml
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: PDS 40 mg/ml
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: PDS 100 mg/ml
Number of subjects: 220

Group type: COMPARATOR
Intervention: Monthly intravitreal ranibizumab 0.5 mg
Number of subjects: 220
Study: 35759134

Group type: EXPERIMENTAL
Intervention: ASP1650 (1000 mg/m)
Number of subjects: 19
Study: 35759279

Group type: EXPERIMENTAL
Intervention: Wearable electrocardiogram and physical activity sensors
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Inoculation with influenza A (H3N2) virus
Number of subjects: 20
Study: 35759721

Group type: EXPERIMENTAL
Intervention: Quantum Diagnostics System (QDS)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Measuring Energy Expenditure in ECMO patients (MEEP)
Number of subjects: 39
Study: 35759791

Group type: EXPERIMENTAL
Intervention: Web-based training and workshops for care teams in interprofessional shared decision-making (1.5-hour tutorial + 3.5-hour workshop)
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Web-based training and workshops for care teams in interprofessional shared decision-making
Number of subjects: 311

Group type: COMPARATOR
Intervention: Passive dissemination of the decision guide
Number of subjects: 311
Study: 35760616

Group type: EXPERIMENTAL
Intervention: Left internal mammary artery (LIMA) graft
Number of subjects: 1068

Group type: EXPERIMENTAL
Intervention: Radial artery graft
Number of subjects: 1068

Group type: EXPERIMENTAL
Intervention: Saphenous vein graft
Number of subjects: 1068

Group type: EXPERIMENTAL
Intervention: Right internal mammary artery (RIMA) graft
Number of subjects: 1068

Group type: COMPARATOR
Intervention: Comparison of RIMA to radial artery and saphenous vein grafts
Number of subjects: 1068
Study: 35760819

Group type: EXPERIMENTAL
Intervention: ARISES smartphone-based platform with deep learning algorithm
Number of subjects: 12

Group type: COMPARATOR
Intervention: Use of wristband data
Number of subjects: 12
Study: 35760920

Group type: EXPERIMENTAL
Intervention: Realgar-Indigo naturalis formula (RIF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Arsenic trioxide
Number of subjects: 0
Study: 35760939

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 vaccination (various vaccines including Gam-COVID-Vac, ChAdOx1 nCoV-19, BBIBP-CorV)
Number of subjects: 1234

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 vaccination
Number of subjects: 1234
Study: 35761234

Group type: EXPERIMENTAL
Intervention: FDC budesonide/formoterol via the Elpenhaler device
Number of subjects: 716
Study: 35761306

Group type: EXPERIMENTAL
Intervention: Psychodynamic Therapy (PDT)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Both PDT and CBT
Number of subjects: 10
Study: 35761404

Group type: EXPERIMENTAL
Intervention: Awake prone positioning (APP)
Number of subjects: 71
Study: 35762292

Group type: EXPERIMENTAL
Intervention: Peripheral nerve block use
Number of subjects: 2678

Group type: COMPARATOR
Intervention: Not applicable (C3 cluster)
Number of subjects: 2678

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 2678
Study: 35762796

Group type: EXPERIMENTAL
Intervention: Tebipenem pivoxil hydrobromide (TBP-PI-HBr)
Number of subjects: 0
Study: 35762834

Group type: EXPERIMENTAL
Intervention: Combination group (interferon beta-1b 16 million units daily and remdesivir 200 mg loading on day 1 followed by 100 mg daily on day 2 to 5)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Combination group
Number of subjects: 212

Group type: COMPARATOR
Intervention: Control group (remdesivir only)
Number of subjects: 212
Study: 35762890

Group type: EXPERIMENTAL
Intervention: Transarterial radioembolization (TARE) with yttrium 90, details on dosage and duration not available.
Number of subjects: 0
Study: 35762891

Group type: EXPERIMENTAL
Intervention: Xenon 129
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (6 participants)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: PACS group (34 participants)
Number of subjects: 40
Study: 35762935

Group type: EXPERIMENTAL
Intervention: Mental health service provider-presented video outreach program
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Peer-presented video outreach program
Number of subjects: 217

Group type: COMPARATOR
Intervention: Wait-list comparison group
Number of subjects: 217
Study: 35763113

Group type: EXPERIMENTAL
Intervention: Galcanezumab
Number of subjects: 155
Study: 35763235

Group type: EXPERIMENTAL
Intervention: Intragastric balloon (IGB) placement
Number of subjects: 56
Study: 35763342

Group type: EXPERIMENTAL
Intervention: Roche HD Digital Monitoring Platform
Number of subjects: 219
Study: 35763351

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol patches (200 µg/day) for 3 weeks postpartum
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo patches for 3 weeks postpartum
Number of subjects: 220
Study: 35763600

Group type: EXPERIMENTAL
Intervention: Fat-free cardiorespiratory fitness (FF-V̇O 2max)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Excess adiposity (visceral adipose tissue [VAT], body mass index [BMI], whole-body percent fat [WB%FAT])
Number of subjects: 121
Study: 35763667

Group type: EXPERIMENTAL
Intervention: Involved-field radiotherapy (IFRT) at a dose of 21-Gy for SERs after 3 chemotherapy cycles.
Number of subjects: 135

Group type: COMPARATOR
Intervention: No involved-field radiotherapy (IFRT) for SERs after 3 chemotherapy cycles.
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Involved-field radiotherapy (IFRT) at a dose of 21-Gy for RERs after 3 chemotherapy cycles.
Number of subjects: 135

Group type: COMPARATOR
Intervention: No involved-field radiotherapy (IFRT) for RERs after 3 chemotherapy cycles.
Number of subjects: 135
Study: 35763768

Group type: EXPERIMENTAL
Intervention: Ultrasound-based evaluations
Number of subjects: 300

Group type: COMPARATOR
Intervention: More expensive techniques (magnetic resonance imaging, positron emission tomography, computed tomography)
Number of subjects: 300
Study: 35763887

Group type: EXPERIMENTAL
Intervention: Unilateral cerebral palsy group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Typically developing children group
Number of subjects: 20
Study: 35764393

Group type: EXPERIMENTAL
Intervention: Third dose of mRNA vaccine administered within 6 months after the second dose
Number of subjects: 108

Group type: COMPARATOR
Intervention: Two doses of mRNA vaccine
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Three doses of mRNA vaccine
Number of subjects: 108
Study: 35764593

Group type: EXPERIMENTAL
Intervention: Metacognitive strategies
Number of subjects: 4936

Group type: EXPERIMENTAL
Intervention: Personality traits (especially neuroticism)
Number of subjects: 4936

Group type: EXPERIMENTAL
Intervention: Metacognitive beliefs and strategies
Number of subjects: 4936

Group type: EXPERIMENTAL
Intervention: Statistical models based on personality traits versus metacognitions
Number of subjects: 4936
Study: 35764638

Group type: EXPERIMENTAL
Intervention: Lentiviral-transduced autologous hematopoietic stem cells following busulfan (6 mg/kg total) conditioning
Number of subjects: 19
Study: 35764637

Group type: EXPERIMENTAL
Intervention: 2 doses of BNT162b2 (BB)
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: 2 doses of CoronaVac (CC)
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: 1 dose of BNT162b2 (B)
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: CoronaVac (CC)
Number of subjects: 239

Group type: COMPARATOR
Intervention: BNT162b2 (BB)
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Both vaccines (BNT162b2 and CoronaVac)
Number of subjects: 239
Study: 35764773

Group type: EXPERIMENTAL
Intervention: Asciminib (total daily dose of 20-400 mg)
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Asciminib (80 mg total daily dose as 40 mg twice daily or 80 mg once daily)
Number of subjects: 353

Group type: COMPARATOR
Intervention: Bosutinib (not specified dosage)
Number of subjects: 353
Study: 35764796

Group type: EXPERIMENTAL
Intervention: Decentralized clinical trial (DCT) with oral anticoagulation adherence (OACA)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Decentralized clinical trial (DCT) with low baseline OACA (<90%)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Engagement metrics from DCT
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Patient feedback from DCT
Number of subjects: 100
Study: 35764995

Group type: EXPERIMENTAL
Intervention: Survey during child's induction (T1)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Survey during maintenance therapy (T2)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Survey near treatment completion (T3)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Optional semi-structured interview
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Annual survey about institution resources
Number of subjects: 15
Study: 35765007

Group type: EXPERIMENTAL
Intervention: Dual block HER2 assessment
Number of subjects: 3806
Study: 35765055

Group type: EXPERIMENTAL
Intervention: Voretigene neparvovec (VN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of Care (SoC)
Number of subjects: 0
Study: 35765145

Group type: EXPERIMENTAL
Intervention: Combination of donor-derived cell-free DNA (dd-cfDNA) fraction and quantity
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Two-variable system (dd-cfDNA fraction and quantity)
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Two-threshold algorithm for molecular diagnoses
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Two-threshold algorithm for histology diagnoses
Number of subjects: 367
Study: 35765711

Group type: EXPERIMENTAL
Intervention: Focused ultrasound (FUS) for striatal blood-brain barrier (BBB) opening
Number of subjects: 7
Study: 35766394

Group type: EXPERIMENTAL
Intervention: Intentional watch and wait (W&W) after neoadjuvant chemoradiotherapy plus consolidation CAPEOX
Number of subjects: 64
Study: 35766641

Group type: EXPERIMENTAL
Intervention: Home BP
Number of subjects: 404

Group type: COMPARATOR
Intervention: Office BP
Number of subjects: 404
Study: 35766976

Group type: EXPERIMENTAL
Intervention: Class 1 glucose response profile
Number of subjects: 2378

Group type: EXPERIMENTAL
Intervention: Class 3 glucose response profile
Number of subjects: 2378

Group type: EXPERIMENTAL
Intervention: Class 4 glucose response profile
Number of subjects: 2378

Group type: EXPERIMENTAL
Intervention: Insulin sensitivity
Number of subjects: 2378

Group type: EXPERIMENTAL
Intervention: β-cell glucose sensitivity
Number of subjects: 2378
Study: 35767123

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) treatment
Number of subjects: 708

Group type: COMPARATOR
Intervention: No inhaled corticosteroids (ICS) treatment
Number of subjects: 708
Study: 35767182

Group type: EXPERIMENTAL
Intervention: Apatinib (500 mg per day)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Apatinib combined with radioactive iodine (RAI) therapy
Number of subjects: 5
Study: 35767205

Group type: EXPERIMENTAL
Intervention: Sitravatinib (10-200 mg)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Sitravatinib (150 mg)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Sitravatinib
Number of subjects: 193
Study: 35767233

Group type: EXPERIMENTAL
Intervention: Transcutaneous monitoring of oxygen (tcpO2)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Transcutaneous monitoring of carbon dioxide (tcpCO2)
Number of subjects: 10
Study: 35767435

Group type: EXPERIMENTAL
Intervention: Early spontaneous breathing during invasive mechanical ventilation (IMV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ventilation strategies avoiding spontaneous breathing (e.g. using NMBA or deep sedation)
Number of subjects: 0
Study: 35767439

Group type: EXPERIMENTAL
Intervention: Oncolytic virus DNX-2401 infusion followed by radiotherapy
Number of subjects: 12
Study: 35768023

Group type: EXPERIMENTAL
Intervention: CT-STAR (cone beam computed tomography-guided stereotactic adaptive radiation therapy)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: CT-STAR
Number of subjects: 8

Group type: COMPARATOR
Intervention: nonadapted CT-guided stereotactic body radiation therapy (SBRT)
Number of subjects: 8
Study: 35768164

Group type: EXPERIMENTAL
Intervention: TCR-transduced T-cell product (TBI-1301) with a dose of 5×10
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TCR-transduced T-cell product (TBI-1301)
Number of subjects: 0
Study: 35768575

Group type: EXPERIMENTAL
Intervention: Visual Body Composition (VBC) using smartphone camera
Number of subjects: 134

Group type: COMPARATOR
Intervention: Other consumer-grade fat measurement devices
Number of subjects: 134
Study: 35768859

Group type: EXPERIMENTAL
Intervention: Ziv-aflibercept 1.25 mg (0.05 ml) administered by intravitreal injection monthly for 6 months
Number of subjects: 40
Study: 35769080

Group type: EXPERIMENTAL
Intervention: Educational Programme (EP) based on outreach visits
Number of subjects: 587

Group type: COMPARATOR
Intervention: Control Group (CG) with no Educational Programme
Number of subjects: 587
Study: 35769244

Group type: EXPERIMENTAL
Intervention: Generic once-daily tacrolimus
Number of subjects: 144
Study: 35769360

Group type: EXPERIMENTAL
Intervention: DISE-guided CPAP titration
Number of subjects: 24

Group type: COMPARATOR
Intervention: CSC CPAP titration
Number of subjects: 24
Study: 35769368

Group type: EXPERIMENTAL
Intervention: Intravenous alteplase treatment
Number of subjects: 503

Group type: COMPARATOR
Intervention: Control group (no alteplase treatment)
Number of subjects: 503
Study: 35769451

Group type: EXPERIMENTAL
Intervention: Family support grant (maximum: $750)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre-conference survey for applicants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-conference survey for recipients
Number of subjects: 0
Study: 35770218

Group type: EXPERIMENTAL
Intervention: Fusion-FFR
Number of subjects: 148

Group type: COMPARATOR
Intervention: CT-FFR
Number of subjects: 148

Group type: COMPARATOR
Intervention: OCT-FFR
Number of subjects: 148
Study: 35770220

Group type: EXPERIMENTAL
Intervention: V-LAP system for left atrial pressure monitoring
Number of subjects: 5
Study: 35770681

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy
Number of subjects: 110
Study: 35770702

Group type: EXPERIMENTAL
Intervention: Participatory comic intervention
Number of subjects: 0
Study: 35770988

Group type: EXPERIMENTAL
Intervention: Remote telehealth intervention (using computers or phones)
Number of subjects: 21
Study: 35771029

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moderate-to vigorous-intensity physical activity (MVPA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Late timing of physical activity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physical activity clustering by intensity and time of day
Number of subjects: 0
Study: 35771259

Group type: EXPERIMENTAL
Intervention: Tepotinib 500 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tepotinib (30-1400 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tepotinib (500 mg and 1000 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tepotinib
Number of subjects: 0
Study: 35771301

Group type: EXPERIMENTAL
Intervention: Aflibercept combined with docetaxel (75 mg/m²)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Docetaxel (75 mg/m²)
Number of subjects: 12
Study: 35771568

Group type: EXPERIMENTAL
Intervention: Lumacaftor/Ivacaftor
Number of subjects: 0
Study: 35771572

Group type: EXPERIMENTAL
Intervention: Decreased default number of opioid doses from 30 to 12 in pediatric otolaryngology patients post-intervention.
Number of subjects: 237
Study: 35771573

Group type: EXPERIMENTAL
Intervention: Venlafaxine extended release (37.5 mg to 300 mg daily for up to 12 weeks)
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Venlafaxine extended release
Number of subjects: 416
Study: 35771832

Group type: EXPERIMENTAL
Intervention: Traditional multitask training (TMT)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Combination of TMT and video game multitask training (VGMT)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Video game multitask training (VGMT)
Number of subjects: 25
Study: 35771872

Group type: EXPERIMENTAL
Intervention: Chatbot-based decision aid combined with screening reminder letters and HPV self-sampling kits.
Number of subjects: 4000

Group type: COMPARATOR
Intervention: Standard of care (reminder letters and HPV self-sampling kits).
Number of subjects: 4000
Study: 35771992

Group type: EXPERIMENTAL
Intervention: Recreational physical activity (PA) prior to and during pregnancy
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Recreational physical activity (PA) during pregnancy
Number of subjects: 298
Study: 35772015

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 35772170

Group type: EXPERIMENTAL
Intervention: Rondoraptivon pegol (3 mg subcutaneously on days 1, 4, and 7, followed by 6 to 9 mg weekly until day 28)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Rondoraptivon pegol
Number of subjects: 5
Study: 35772177

Group type: EXPERIMENTAL
Intervention: O3AEE (omega-3-acid ethyl esters) 2 g/day
Number of subjects: 13864

Group type: COMPARATOR
Intervention: Non-O3AEE (control group)
Number of subjects: 13864